Retrospective Analysis on the Feasibility and Efficacy of Docetaxel-Cisplatin Therapy for Recurrent Endometrial Cancer

Tomomi Ninomiya, Wataru Yamagami, Nobuyuki Susumu, Takeshi Makabe, Kensuke Sakai, Michiko Wada, Aya Takigawa, Tatsuyuki Chiyoda, Hiroyuki Nomura, Fumio Kataoka, Akira Hirasawa, Kouji Banno, Daisuke Aoki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

AIM: There is poor evidence regarding effective treatment for recurrent endometrial cancer. We treated patients with recurrent endometrial cancer with docetaxel-cisplatin (DP) therapy as second-line or third-line chemotherapy. We aimed to evaluate the feasibility and efficacy of DP therapy for patients with recurrent endometrial cancer.

PATIENT AND METHODS: We included 26 patients diagnosed with recurrent endometrial cancer, who underwent DP chemotherapy at our Institution. Docetaxel at 70 mg/m(2)and cisplatin at 60 mg/m(2)were administered by intravenous injection every 3 weeks. We retrospectively analyzed the clinicopathological factors associated with the response rate (RR) and prognosis. We also analyzed the adverse effects of DP therapy.

RESULTS: Median follow-up was 33.8 months and the median number of therapy cycles was six. Grade 3 or 4 adverse effects included leukopenia (66%), neutropenia (81%), anemia (9%), diarrhea (12%), general fatigue (12%), liver dysfunction (4%), peripheral neuropathy (4%), and hyponatremia (4%). RR was 58% and the median progression-free survival (PFS) was 7.5 months. The group with a treatment-free interval of 6 months or more tended to have better PFS than that with less than 6 months (p=0.01). The group with a platinum-free interval of 6 months or more had significantly better PFS than that with less than 6 months (p=0.09). Although the history of taxane usage was not relevant to prognosis, a taxane-free interval of 12 months or more was associated with a tendency for better PFS (p=0.06).

CONCLUSION: DP therapy was fully feasible and demonstrated efficacy for patients with recurrent endometrial cancer.

Original languageEnglish
Pages (from-to)1751-1758
Number of pages8
JournalAnticancer Research
Volume36
Issue number4
Publication statusPublished - 2016 Apr 1

Fingerprint

docetaxel
Endometrial Neoplasms
Cisplatin
Disease-Free Survival
Therapeutics
Drug Therapy
Hyponatremia
Leukopenia
Peripheral Nervous System Diseases
Neutropenia
Platinum
Intravenous Injections
Fatigue
Liver Diseases
Anemia
Diarrhea

Keywords

  • cisplatin
  • docetaxel
  • Endometrial cancer
  • recurrent

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Retrospective Analysis on the Feasibility and Efficacy of Docetaxel-Cisplatin Therapy for Recurrent Endometrial Cancer. / Ninomiya, Tomomi; Yamagami, Wataru; Susumu, Nobuyuki; Makabe, Takeshi; Sakai, Kensuke; Wada, Michiko; Takigawa, Aya; Chiyoda, Tatsuyuki; Nomura, Hiroyuki; Kataoka, Fumio; Hirasawa, Akira; Banno, Kouji; Aoki, Daisuke.

In: Anticancer Research, Vol. 36, No. 4, 01.04.2016, p. 1751-1758.

Research output: Contribution to journalArticle

Ninomiya, T, Yamagami, W, Susumu, N, Makabe, T, Sakai, K, Wada, M, Takigawa, A, Chiyoda, T, Nomura, H, Kataoka, F, Hirasawa, A, Banno, K & Aoki, D 2016, 'Retrospective Analysis on the Feasibility and Efficacy of Docetaxel-Cisplatin Therapy for Recurrent Endometrial Cancer', Anticancer Research, vol. 36, no. 4, pp. 1751-1758.
Ninomiya, Tomomi ; Yamagami, Wataru ; Susumu, Nobuyuki ; Makabe, Takeshi ; Sakai, Kensuke ; Wada, Michiko ; Takigawa, Aya ; Chiyoda, Tatsuyuki ; Nomura, Hiroyuki ; Kataoka, Fumio ; Hirasawa, Akira ; Banno, Kouji ; Aoki, Daisuke. / Retrospective Analysis on the Feasibility and Efficacy of Docetaxel-Cisplatin Therapy for Recurrent Endometrial Cancer. In: Anticancer Research. 2016 ; Vol. 36, No. 4. pp. 1751-1758.
@article{0c7036da1d3d46bda2d8b7e678692073,
title = "Retrospective Analysis on the Feasibility and Efficacy of Docetaxel-Cisplatin Therapy for Recurrent Endometrial Cancer",
abstract = "AIM: There is poor evidence regarding effective treatment for recurrent endometrial cancer. We treated patients with recurrent endometrial cancer with docetaxel-cisplatin (DP) therapy as second-line or third-line chemotherapy. We aimed to evaluate the feasibility and efficacy of DP therapy for patients with recurrent endometrial cancer.PATIENT AND METHODS: We included 26 patients diagnosed with recurrent endometrial cancer, who underwent DP chemotherapy at our Institution. Docetaxel at 70 mg/m(2)and cisplatin at 60 mg/m(2)were administered by intravenous injection every 3 weeks. We retrospectively analyzed the clinicopathological factors associated with the response rate (RR) and prognosis. We also analyzed the adverse effects of DP therapy.RESULTS: Median follow-up was 33.8 months and the median number of therapy cycles was six. Grade 3 or 4 adverse effects included leukopenia (66{\%}), neutropenia (81{\%}), anemia (9{\%}), diarrhea (12{\%}), general fatigue (12{\%}), liver dysfunction (4{\%}), peripheral neuropathy (4{\%}), and hyponatremia (4{\%}). RR was 58{\%} and the median progression-free survival (PFS) was 7.5 months. The group with a treatment-free interval of 6 months or more tended to have better PFS than that with less than 6 months (p=0.01). The group with a platinum-free interval of 6 months or more had significantly better PFS than that with less than 6 months (p=0.09). Although the history of taxane usage was not relevant to prognosis, a taxane-free interval of 12 months or more was associated with a tendency for better PFS (p=0.06).CONCLUSION: DP therapy was fully feasible and demonstrated efficacy for patients with recurrent endometrial cancer.",
keywords = "cisplatin, docetaxel, Endometrial cancer, recurrent",
author = "Tomomi Ninomiya and Wataru Yamagami and Nobuyuki Susumu and Takeshi Makabe and Kensuke Sakai and Michiko Wada and Aya Takigawa and Tatsuyuki Chiyoda and Hiroyuki Nomura and Fumio Kataoka and Akira Hirasawa and Kouji Banno and Daisuke Aoki",
year = "2016",
month = "4",
day = "1",
language = "English",
volume = "36",
pages = "1751--1758",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Retrospective Analysis on the Feasibility and Efficacy of Docetaxel-Cisplatin Therapy for Recurrent Endometrial Cancer

AU - Ninomiya, Tomomi

AU - Yamagami, Wataru

AU - Susumu, Nobuyuki

AU - Makabe, Takeshi

AU - Sakai, Kensuke

AU - Wada, Michiko

AU - Takigawa, Aya

AU - Chiyoda, Tatsuyuki

AU - Nomura, Hiroyuki

AU - Kataoka, Fumio

AU - Hirasawa, Akira

AU - Banno, Kouji

AU - Aoki, Daisuke

PY - 2016/4/1

Y1 - 2016/4/1

N2 - AIM: There is poor evidence regarding effective treatment for recurrent endometrial cancer. We treated patients with recurrent endometrial cancer with docetaxel-cisplatin (DP) therapy as second-line or third-line chemotherapy. We aimed to evaluate the feasibility and efficacy of DP therapy for patients with recurrent endometrial cancer.PATIENT AND METHODS: We included 26 patients diagnosed with recurrent endometrial cancer, who underwent DP chemotherapy at our Institution. Docetaxel at 70 mg/m(2)and cisplatin at 60 mg/m(2)were administered by intravenous injection every 3 weeks. We retrospectively analyzed the clinicopathological factors associated with the response rate (RR) and prognosis. We also analyzed the adverse effects of DP therapy.RESULTS: Median follow-up was 33.8 months and the median number of therapy cycles was six. Grade 3 or 4 adverse effects included leukopenia (66%), neutropenia (81%), anemia (9%), diarrhea (12%), general fatigue (12%), liver dysfunction (4%), peripheral neuropathy (4%), and hyponatremia (4%). RR was 58% and the median progression-free survival (PFS) was 7.5 months. The group with a treatment-free interval of 6 months or more tended to have better PFS than that with less than 6 months (p=0.01). The group with a platinum-free interval of 6 months or more had significantly better PFS than that with less than 6 months (p=0.09). Although the history of taxane usage was not relevant to prognosis, a taxane-free interval of 12 months or more was associated with a tendency for better PFS (p=0.06).CONCLUSION: DP therapy was fully feasible and demonstrated efficacy for patients with recurrent endometrial cancer.

AB - AIM: There is poor evidence regarding effective treatment for recurrent endometrial cancer. We treated patients with recurrent endometrial cancer with docetaxel-cisplatin (DP) therapy as second-line or third-line chemotherapy. We aimed to evaluate the feasibility and efficacy of DP therapy for patients with recurrent endometrial cancer.PATIENT AND METHODS: We included 26 patients diagnosed with recurrent endometrial cancer, who underwent DP chemotherapy at our Institution. Docetaxel at 70 mg/m(2)and cisplatin at 60 mg/m(2)were administered by intravenous injection every 3 weeks. We retrospectively analyzed the clinicopathological factors associated with the response rate (RR) and prognosis. We also analyzed the adverse effects of DP therapy.RESULTS: Median follow-up was 33.8 months and the median number of therapy cycles was six. Grade 3 or 4 adverse effects included leukopenia (66%), neutropenia (81%), anemia (9%), diarrhea (12%), general fatigue (12%), liver dysfunction (4%), peripheral neuropathy (4%), and hyponatremia (4%). RR was 58% and the median progression-free survival (PFS) was 7.5 months. The group with a treatment-free interval of 6 months or more tended to have better PFS than that with less than 6 months (p=0.01). The group with a platinum-free interval of 6 months or more had significantly better PFS than that with less than 6 months (p=0.09). Although the history of taxane usage was not relevant to prognosis, a taxane-free interval of 12 months or more was associated with a tendency for better PFS (p=0.06).CONCLUSION: DP therapy was fully feasible and demonstrated efficacy for patients with recurrent endometrial cancer.

KW - cisplatin

KW - docetaxel

KW - Endometrial cancer

KW - recurrent

UR - http://www.scopus.com/inward/record.url?scp=84983006900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983006900&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 1751

EP - 1758

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -